Design Therapeutics
DSGN
98 hedge funds and large institutions have $133M invested in Design Therapeutics in 2025 Q1 according to their latest regulatory filings, with 13 funds opening new positions, 28 increasing their positions, 37 reducing their positions, and 10 closing their positions.
30% more first-time investments, than exits
New positions opened: 13 | Existing positions closed: 10
3% more funds holding
Funds holding: 95 → 98 (+3)
1.61% more ownership
Funds ownership: 59.1% → 60.71% (+1.6%)
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
12% less call options, than puts
Call options by funds: $15K | Put options by funds: $17K
24% less repeat investments, than reductions
Existing positions increased: 28 | Existing positions reduced: 37
36% less capital invested
Capital invested by funds: $206M → $133M (-$73.4M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
KCM
Kynam Capital Management
Princeton,
New Jersey
|
+$4.31M |
| 2 |
WP
Woodline Partners
San Francisco,
California
|
+$3.08M |
| 3 |
TCM
Tang Capital Management
San Diego,
California
|
+$954K |
| 4 |
Wellington Management Group
Boston,
Massachusetts
|
+$675K |
| 5 |
DCM
Driehaus Capital Management
Chicago,
Illinois
|
+$655K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
EC
EcoR1 Capital
San Francisco,
California
|
-$2.63M |
| 2 |
Walleye Capital
New York
|
-$871K |
| 3 |
D.E. Shaw & Co
New York
|
-$559K |
| 4 |
BlackRock
New York
|
-$475K |
| 5 |
Morgan Stanley
New York
|
-$469K |
DSGN Hedge Fund Activity: Q1 2025 in Review
98 of the 7,459 institutional investors tracked by Wall St. Rank reported a position in Design Therapeutics (DSGN) for Q1 2025, worth a combined $133M — down 36% from $206M a quarter earlier.
Buyers outnumbered sellers: 13 funds opened new DSGN positions and 10 closed out — a net gain of 3 holders — while 28 added to existing stakes and 37 trimmed.
The largest buyer was Kynam Capital Management, opening a new position worth an estimated $4.31M. The largest seller was EcoR1 Capital, exiting entirely with an estimated $2.63M sold.
- 98 institutional investors held Design Therapeutics (DSGN) as of Q1 2025, up from 95 in Q4 2024.
- Funds reported $133M of Design Therapeutics stock for Q1 2025, down 36% quarter-over-quarter.
- 13 funds opened new Design Therapeutics positions in Q1 2025 and 10 closed out, a net change of +3 holders.
- The largest Design Therapeutics buyer in Q1 2025 was Kynam Capital Management, an estimated $4.31M added.
- The largest Design Therapeutics seller in Q1 2025 was EcoR1 Capital, an estimated $2.63M sold.
Based on aggregated 13F filings for Q1 2025.